1. Antibacterial efficacy of fractions and compounds from Indigofera barberi: Identification of DNA gyrase B inhibitors through pharmacophore based virtual screening
- Author
-
Aluru Ram Mohan, Thirunavakkarasu Sivaraman, Baki Vijaya Bhaskar, Cherukupalle Bhuvaneswar, Sivarathri Siva Rajesh, Tirumalasetty Muni Chandra Babu, Wudayagiri Rajendra, and Duvvuru Gunasekar
- Subjects
0301 basic medicine ,Virtual screening ,030106 microbiology ,Bioengineering ,Biology ,Antimicrobial ,Applied Microbiology and Biotechnology ,Biochemistry ,DNA gyrase ,Multiple drug resistance ,03 medical and health sciences ,chemistry.chemical_compound ,030104 developmental biology ,chemistry ,Docking (molecular) ,Lipinski's rule of five ,Pharmacophore ,Quercetin - Abstract
Multidrug resistant (MDR) gram negative bacterial infections are most prevalent in the hospitals which are truly untreatable and remedial verdict are very deprived. In the current investigation, two compounds (Quercetin and Pinitol) and fractions have been isolated and characterized from Indigofera barberi using chromatographic and NMR studies. Antimicrobial assays reveal IB-Me, IB-D and IB-E fractions and quercetin have shown eloquent antimicrobial activity on clinically isolated bacteria such as Pseudomonas aeruginosa, E. coli, Klebsiella pneumonia and Citrobacter sp. Molecular docking studies demonstrated quercetin has exhibited highest binding affinity with DNA gyrase B and subsequently eleven pharmacophore features viz . five HBD/HBA, two hydrophobic, one HBA and three aromatic (Pi) rings were identified using MOE. Pharmacophore based virtual screening, docking, binding energies and binding affinity with Born-volume (GB/VI) studies demonstrated thirteen lead molecules which were specifically interacted with Asn46, Asp73, Arg76, Thr163, Lys103, Arg136 residues and conserved water molecules within ATP pocket of DNA gyrase B. These scaffolds comply with Lipinski rule of five, toxicity and drug likeness properties deliberated as drug compounds. Hence, these compounds could be endorsed as persuasive DNA gyrase B inhibitors which can be considered as novel compounds in the clinical management of MDR Gram negative bacterial infections.
- Published
- 2016
- Full Text
- View/download PDF